---
schema_version: "secwatch.filing_event.v1"
accession: "0001493152-24-047145"
form_type: "8-K"
ticker: "TELO"
cik: "0001971532"
company_name: "Telomir Pharmaceuticals, Inc."
filed_at: "2024-11-21T23:59:59+00:00"
generated_at: "2026-05-29T21:20:32.068395+00:00"
event_type: "leadership"
sentiment: "neutral"
materiality_score: 0.5
calibrated_materiality_score: 0.5
confidence: "high"
source: SEC EDGAR
---

# Telomir Pharma announces resignation of director Michael Jerman; replaces audit committee roles

## Summary
- On November 18, 2024, Michael Jerman resigned from the Board and as Chair of the Audit Committee, effective immediately, to pursue other activities, not due to a disagreement.
- On November 20, 2024, the Board appointed Dr. Matthew Del Giudice to the Audit Committee to fill the vacancy.
- The Board also appointed Matthew Pratt Whalen as Chairman of the Audit Committee.
- No exhibits other than the Fifth Refinancing Amendment (not attached here) were filed.

## SEC filing metadata
- accession: 0001493152-24-047145
- form_type: 8-K
- ticker: TELO
- cik: 0001971532
- company_name: Telomir Pharmaceuticals, Inc.
- filed_at: 2024-11-21T23:59:59+00:00
- event_type: leadership
- sentiment: neutral
- materiality_score: 0.5
- calibrated_materiality_score: 0.5
- confidence: high
- sec_items: 5.02
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1971532/000149315224047145/0001493152-24-047145-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1971532/000149315224047145/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001493152-24-047145
- JSON: https://secwatch.observer/filing/0001493152-24-047145.json
- Plain text: https://secwatch.observer/filing/0001493152-24-047145.txt

## Key facts
- Executive change
  Michael Jerman resigned as Member of the Board of Directors and Chair of the Audit Committee at Telomir Pharmaceuticals, Inc..
  - Action: resigned
  - Role: Member of the Board of Directors and Chair of the Audit Committee
  source text: On November 18, 2024, Telomir Pharmaceuticals, Inc. (the “ Company ”) received written notice of resignation from Michael Jerman resigning, with immediate effect, from his positions a member of the Board of Directors of the Company (the “ Board ”) and as Chair of the Audit Committee
  evidence_url: https://www.sec.gov/Archives/edgar/data/1971532/000149315224047145/0001493152-24-047145-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.